Fresenius Partners with WuXi Biologics to Expand Biosimilar Pipeline
Fresenius SE & Co. KGaA has entered into an exclusive development agreement with WuXi Biologics to expand its biosimilar drug pipeline, with access to up to 37 potential new…
Read More...
Read More...
